By TIOL News Service

NEW DELHI, JULY 31, 2020: MINISTER of Science &Technology, Earth Sciences and Health & Family Welfare, Dr Harsh Vardhan, has announced that Indian scientists from DBT & CSIR have sequenced more than 1000 SARS-CoV-2 viral genomes making it the largest effort in the country. “This will help in understanding the prevalent strains and the mutation spectrum in India, which will help in diagnostics, drugs and vaccines”, he said.

Dr. Harsh Vardhan was speaking while releasing a compendium of Covid-19 technologies and products developed by CSIR, at a function here yesterday. The compendium covers a wide range of technologies and products spanning from diagnostics to drugs to ventilators and PPEs with more than 100 technologies, 93 industry partners listed and with over 60 of these technologies have been transferred to industry.  

Dr Harsh Vardhan observed that “The portfolio of technologies and products developed in a short time are a testament to the capabilities of CSIR scientists and that they can deliver in most difficult of the circumstances”. He complimented the efforts of the scientists, students and staff of CSIR for developing these technologies and products at such short notice in these challenging conditions. He said that “The compendium brought out by CSIR captures the technologies and products well in one place and can help industries and other agencies who are seeking solutions for Covid-19 to access them easily.”

Expressing his satisfaction, the Minister said, “CSIR has made significant contributions to India's fight against Covid-19 on various fronts ranging from augmenting testing capacity to developing novel diagnostics and making affordable repurposed drugs available to patients in partnership with industry”. “ Further, CSIR has developed many hospital assistive devices such as ventilators and PPEs for which a shortage was felt early on in the pandemic”, he said and added that “Now CSIR has compiled a compendium which captures the technologies, products and know-how developed for mitigation of Covid-19 pandemic.”

Dr Harsh Vardhan also complimented the role of CSIR in bringing repurposed drugs against Covid-19 to patients at the earliest in partnership with industry such as Cipla for Favipiravir. He emphasized that efforts such as these will benefit Covid19 patients by making the drugs affordable.  “CSIR-IICT has developed a cost-effective synthetic process technology for Active Pharmaceutical Ingredient (API) of Favipiravir using locally available chemicals and transferred the technology to Cipla who scaled up and manufactured the drug based on this technology”, he said.